Study of antacid effect of the drug Antareit® in healthy volunteers

The aim. Study of pharmacodynamic parameters and confirmation of pharmacodynamic equivalence (bioequivalence) of the drugs Antareit® (INN: magaldrate), chewable tablets, 800 mg (Valenta Pharm JSC, Russia) and Riopan (INN magaldrate), chewable tablets, 800 mg (Takeda GmbH, Germany). Material and methods. An open randomized crossover study was conducted to investigate the pharmacodynamics of the study drug Antareit® and the reference drug Riopan, assessing their bioequivalence after taking 2 chewable tablets of the study or reference drug 3 times a day. The study involved 40 healthy volunteers who were randomized into 2 groups of 20 people depending on the sequence of drug administration in study periods I and II. Intragastric acidity was measured with a pH-probe within 30 minutes before and for one hour after taking the study drugs. Based on the data obtained, 90% confidence intervals (CI) were calculated for the pharmacodynamic parameter AUCABL, reflecting the area above the baseline pH. The safety of the study drugs was assessed by the frequency and severity of adverse events (AEs). Results. Statistical analysis showed that the 90% CI for the ratio of the mean values of the AUC ABL parameter of the study drug to the reference drug did not fall below 80% (90% CI: 80.55–119.49). During the study, 18 adverse events (AEs) were reported in 15.4% (6 of 39) of volunteers in the safety population, and there were no statistically significant differences in the incidence of AEs between groups, nor in the incidence of AEs depending on the drug taken. Conclusion. The studied drugs are pharmacodynamically equivalent and have a similar safety profile when administered repeatedly.

1. Полунина Т.В. Комбинированная терапия кислотозависимых заболеваний. РМЖ. 2013;21(13):691–697. Polunina TV. Combination therapy for acid-related diseases. RMJ. 2013;21(13):691–697. (In Russ.).

2. Диагностика и лечение кислотозависимых заболеваний пищеварительного тракта: Руководство для врачей / И.Ю. Колесникова, В.С. Волков. М.: ООО «Издательство «Медицинское информационное агентство», 2014. 432 с. (In Russ.). Diagnostika i lechenie kislotozavisimyh zabolevanij pishchevaritel'nogo trakta: Rukovodstvo dlya vrachej / IYu Kolesnikova, VS Volkov. Moscow: Publishing House "Medical Information Agency" LLC, 2014. (In Russ.).

3. Вьючнова Е.С., Никушкина И.Н., Одинцова А.Н., и др. Современные представления о роли антацидных препаратов в лечении кислотозависимых заболеваний. Доказательная гастроэнтерология. 2014;3(3):73–75. V'iuchnova ES, Nikushina IN, Odintsova AN, et al. The current concepts of the role of antacid preparations in the treatment of acid-dependent diseases. Russian Journal of Evidence-Based Gastroenterology. 2014;3(3):73–75. (In Russ.).

4. GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jun;5(6):561–581. DOI: 10.1016/S2468-1253(19)30408-X.

5. Ушкалова Е.А. Клиническая фармакология современных антацидов. Фарматека. 2006;126(11):1–6. Ushkalova EA. Clinical pharmacology of modern antacids. Farmateka. 2006;126(11):1–6. (In Russ.).

6. Бордин Д.С., Абдулхаков Р.А., Осипенко М.Ф., и др. Многоцентровое исследование распространенности симптомов гастроэзофагеальной рефлюксной болезни у пациентов поликлиник в России. Терапевтический архив. 2022;94(1):48–56. DOI: 10.26442/00403660.2022.01.201322. Bordin DS, Abdulkhakov RA, Osipenko MF, et al. Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):48–56. DOI: 10.26442/00403660.2022.01.2013227.

7. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70– 97. DOI: 10.22416/1382-4376-2020-30-4-70-97. Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.). DOI: 10.22416/1382-4376-2020-30-4-70-97.

8. Булгаков С.А. Клиническое применение антацида магалдрат в лечении кислотозависимых заболеваний. Доказательная гастроэнтерология. 2019;8(3):38–44. DOI: 10.17116/dokgastro2019803138. Bulgakov SA. Clinical application of magaldrate antacid in the treatment of acid-dependent diseases. Russian Journal of Evidence-Based Gastroenterology. 2019;8(3):38–44. (In Russ.). DOI: 10.17116/dokgastro2019803138

9. Громова О.А., Торшин И.Ю., Максимов В.А. Магалдрат как антацид с мультитаргетным воздействием: клинико-фармакологическое эссе. Лечащий Врач. 2018;(2):67–73.Gromova OA, Torshin IYu, Maksimov VA. Magaldrate as an antiacid with multi-target effect: clinical-pharmacological essay. Lechaschi Vrach. 2018;(2):67. (In Russ.).

10. Schmidt C, Baumeister B, Kipnowski J, Miederer SE, Vetter H. Magaldrate stimulates endogenous prostaglandin E2 synthesis in human gastric mucosa in vitro and in vivo. Hepatogastroenterology. 1998 NovDec;45(24):2443–2446.

11. Borella LE, DiJoseph JF, Mir GN. Cytoprotective and antiulcer activities of the antacid magaldrate in the rat. Arzneimittelforschung. 1989 Jul;39(7):786–789. PMID: 2783181.

12. Baur C, Becker A, Linder R, Schwan T. Zur Neutralisationskapazität, Pepsin-Inaktivierung sowie Gallensäure- und Lysolecithin-Bindung des Antazidums Magaldrat [Neutralizing capacity, pepsin inactivation and binding to bile acids and lysolecithin of the antacid magaldrate (author's transl)]. Arzneimittelforschung. 1981;31(3):504–507. German.

13. McCafferty DF, Woolfson AD. A comparative assessment of a new antacid formulation based on magaldrate. J Clin Hosp Pharm. 1983 Dec;8(4):349–355. DOI: 10.1111/j.1365-2710.1983.tb01058.x.

14. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990 Aug;99(2):345–351. DOI: 10.1016/0016-5085(90)91015-x.

15. Трухманов А.С., Сторонова О.А., Ивашкин В.Т. Клиническое значение 24-часовой рН-метрии в диагностике и оценке эффективности лекарственных препаратов у больных с заболеваниями пищевода и желудка. Рос журн гастроэнтерол гепатол колопроктол 2016;26(6):55–68. DOI: 10.22416/1382-4376-2016-6-55-68. Trukhmanov AS, Storonova OA, Ivashkin VT. Clinical impact of 24-hour pH-metry in esophageal and stomach diseases diagnostics and pharmacological drugs efficacy testing. Ross z gastroenterol gepatol koloproktol. 2016; 26(6): 55–68 (In Russ.). DOI: 10.22416/1382-4376-2016-6-55-68.

16. Опарин А.А., Лаврова Н.В., Корниенко Д.А. Особенности моторно-секреторных нарушений при различных формах гастроэзофагеальной рефлюксной болезни. Вестник проблем биологии и медицины. 2013;1(3):131–133. Oparin AA, Lavrova NV, Kornienko DA. Features of Motility and Secretory Disorders in Different Forms of Gastroesophageal Reflux Disease. Bulletin of problems in biology and medicine. 2013;1(3):131–133. (In Russ.).

17. Галиев Ш.З., Амиров Н.Б., Ахметов Т.Р., и др. Характер морфологических изменений слизистой оболочки желудка при дуоденогастральном рефлюксе: взаимосвязь с кислотностью и helicobacter pylori. Уральский медицинский журнал. 2018;(2):91–96. Galiev ShZ, Amirov NB, Akhmetov TR, et al. Morphological changes of the gastric mucosa in patients with duodenogasric reflux: relationship with acidity and helicobacter pylori. Ural Medical Journal. 2018;(2):91–96. (In Russ.).

18. Решение Совета Евразийской Экономической Комиссии № 85 от 03.11.2016 «Об утверждении правил проведения исследований биоэквивалентности лекарственных препаратов в рамках Евразийского экономического союза». Decision of Council of the Eurasian Economic Commission of November 3, 2016 No. 85 «About approval of Rules of carrying out researches of bioequivalence of medicines within the Eurasian Economic Union» (In Russ.).